Concepedia

Nadia Garman

NG

Statistics

Publications

5

Citations

220

H-Index

5

Active since

2017

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

GlaxoSmithKline (United States)

Nadia Garman is an author at GlaxoSmithKline (United Kingdom) specializing in pharmacotherapy, medicine, and drug discovery.

Top concepts

Publications per year

2017–2019

5

Publications

5

Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)

Pauline T. Lukey, Christopher Coello, Roger N. Gunn et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 63 citations · Full text

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants

Charlotte Maden, David Fairman, Michelle Chalker et al. · European Journal of Clinical Pharmacology · 2018 · 62 citations · Full text

, , +7

Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID

Heide A. Stirnadel-Farrant, Mahesh Kudari, Nadia Garman et al. · Orphanet Journal of Rare Diseases · 2018 · 41 citations · Full text

A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of<sup>18</sup>F-FB-A20FMDV2 for Imaging the Integrin α<sub>v</sub>β<sub>6</sub>

Nicholas Keat, Julia Kenny, Keguan Chen et al. · Journal of Nuclear Medicine Technology · 2018 · 29 citations · Full text

Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring

Elaine Irving, Rutger van den Bor, Paco M J Welsing et al. · Journal of Clinical Epidemiology · 2017 · 25 citations · Full text

1–5 of 5